Cooperative Agreement UG3CA305778
Award Date 9/8/25
Completion Date 8/31/27
Dollars Obligated $1.5M
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Aurora, CO 80045, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a $1,684,165 Cooperative Agreement under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) to Kaiser Foundation Hospitals. The project, titled "Expanding Lung Cancer Screening to Achieve Excellence (EXHALE)", aims to develop and evaluate implementation strategies to increase guideline-concordant lung cancer screening in Federally Qualified Health Centers (FQHCs). The project will form a partnership between 7 FQHC...
- The National Cancer Institute awarded a $1,593,217 Cooperative Agreement to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353). The objective of this I-LEARN study is to compare the effectiveness of different selection approaches and tailoring of implementation strategies to increase the scale and sustainment of high-quality lung cancer...
- This federal Cooperative Agreement award is from the National Cancer Institute (NCI), under the 21st Century Cures Act - Beau Biden Cancer Moonshot federal grant program (CFDA 93.353). The $1,594,797 award supports a project to evaluate strategies for scaling up and sustaining tobacco use treatment (TUT) in cancer survivors across a network of 72 clinics. The project aims to adapt and refine implementation strategies, harmonize outcome measures, and establish the feasibility of a multi-stage...
- This federal Project Grant award of $429,399 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will fund research to "RECALIBRATE THE LUNG CANCER POLICY MODEL (LCPM) TO ADDRESS LUNG CANCER RISK AND LUNG CANCER SCREENING PRACTICES IN REAL-WORLD POPULATIONS." The goal is to improve the LCPM's accuracy in estimating the health and economic impacts of low-dose computed tomography (LDCT) lung cancer screening by 1) adjusting the model to reflect...
- The U.S. National Cancer Institute (NCI) awarded a $158,290 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to Kaiser Foundation Hospitals to conduct a study on "Estimating Overdiagnosis After Implementation of Lung Cancer Screening in Community-Based Healthcare Systems." This 2-year project, running from July 2024 to July 2026, aims to produce estimates of overdiagnosis among patients diagnosed with lung cancer who participated in lung cancer...
- This Cooperative Agreement was awarded by the National Cancer Institute (NCI), part of the Department of Health and Human Services' National Institutes of Health, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The $525,013 award will fund research to validate blood-based biomarkers for assessing lung cancer risk among individuals with no smoking history, using samples from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. The research aims to...
- This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $602,315.00 in funding to the University of Colorado-Denver to validate the human relevance of a novel mouse model of lung squamous cell carcinoma (SCC) premalignancy and to use this model to screen and test lung cancer prevention agents. The project aims to incorporate tissue from the improved mouse model into a bioengineered precision cut lung slice model to maintain the...
- This Project Grant award of $1,131,820.00 from the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) supports research to characterize toxicities and health-related quality of life outcomes among a diverse sample of 416 individuals receiving immune checkpoint inhibitor treatment for metastatic cancer. The study aims to examine associations between patient sociodemographic/medical factors and symptomatic toxicities and quality of...
- This Project Grant award, totaling $158,365, was provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395). The grant supports research to understand the impact of NRF2 activation on the initiation and progression of lung squamous cell carcinoma (LUSC). The primary awardee, the University of North Carolina at Chapel Hill, will develop a novel genetically-engineered mouse model to test how an activated NRF2 mutation affects LUSC incidence, tumor...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $399,998 to Darwin Biosciences, Inc. to develop a low-cost, handheld, and non-invasive lung cancer screening device for use in low-resource settings. The device will incorporate sample collection, nucleic acid biomarker detection via isothermal recombinase polymerase amplification, and a visual readout on lateral flow strips. This work builds on Darwin Biosciences' prior...